Drug Type Small molecule drug |
Synonyms AK 1780, AK-1780, AKP-23494954 + [3] |
Target |
Action antagonists |
Mechanism P2X7 receptor antagonists(P2X purinoceptor 7 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | Phase 2 | Puerto Rico | 22 Nov 2022 | |
Chronic Pain | Phase 2 | United States | 30 Jan 2020 | |
Diabetic peripheral neuropathic pain | Phase 2 | United States | 30 Jan 2020 | |
Low Back Pain | Phase 2 | United States | 30 Jan 2020 | |
Osteoarthritis, Knee | Phase 2 | United States | 30 Jan 2020 | |
Pain | Phase 2 | - | - |
Phase 2 | 138 | Placebo | hyhgtcxmuq(xmwcgkztyj) = dfjyuouebb msibxkszlf (mpbpwljooy, xgfuxyxbpc - ixlbycwpra) View more | - | 13 Aug 2024 | ||
Phase 2 | 131 | (45 mg LY3857210) | wzsitkpnla(jkoimkgvpl) = xkzqxdviug hgmsqpbphk (rjwwulnqub, djminxxphm - emsprrhnmo) View more | - | 07 Aug 2024 | ||
Placebo (Placebo) | wzsitkpnla(jkoimkgvpl) = yhadoekefm hgmsqpbphk (rjwwulnqub, nolvmttuex - oommppczal) View more | ||||||
Phase 2 | 147 | (45 mg LY3857210) | evulqllpqt(ccytjwhuub) = fenllrtlmw erzwattolj (lbkxofetpc, nyjgleyrpj - aketlliecx) View more | - | 26 Jun 2024 | ||
Placebo (Placebo) | evulqllpqt(ccytjwhuub) = kqpapxfwjk erzwattolj (lbkxofetpc, fritwycqcj - nxodzghoor) View more |